Selective activation of AMPK β1-containing isoforms improves kidney function in a rat model of diabetic nephropathy

Journal of Pharmacology and Experimental Therapeutics

Volumn 361, Issue 2, 2017, Pages 303-311

  Salatto, Christopher T ^a   Miller, Russell A ^a   Cameron, Kimberly O ^a   Cokorinos, Emily ^a   Reyes, Allan ^a   Ward, Jessica ^a   Calabrese, Matthew F ^a   Kurumbail, Ravi G ^a   Rajamohan, Francis ^a   Kalgutkar, Amit S ^a   Tess, David A ^a   Shavnya, Andre ^a   Genung, Nathan E ^a   Edmonds, David J ^a   Jatkar, Aditi ^a   Maciejewski, Benjamin S ^a   Amaro, Marina ^a   Gandhok, Harmeet ^a   Monetti, Mara ^a   Cialdea, Katherine ^a   Bollinger, Eliza ^a   Kreeger, John M ^a   Coskran, Timothy M ^a   Opsahl, Alan C ^a   Boucher, Germaine G ^a   Birnbaum, Morris J ^a   DaSilva Jardine, Paul ^a   Rolph, Tim ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ACTIVATOR; INSULIN; KIDNEY INJURY MOLECULE 1; PF 06409577; PF 249; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN; RAMIPRIL; SERINE; SMALL INTERFERING RNA; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THREONINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; ENZYME ACTIVATOR; INDOLE DERIVATIVE; ISOENZYME; PF-249; PF-6409577;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIABETIC NEPHROPATHY; DISSOCIATION ENHANCED LANTHANIDE FLUORESCENT IMMUNOASSAY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; KIDNEY FUNCTION; MALE; MOUSE; NONHUMAN; OBESITY; PHARMACODYNAMICS; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEINURIA; RAT; URINARY ALBUMIN CREATININE RATIO; URINARY PROTEIN CREATININE RATIO; UROGENITAL SYSTEM PARAMETERS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL SIZE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; ENZYME ACTIVATION; FIBROSIS; KIDNEY; KIDNEY FUNCTION TEST; MACACA FASCICULARIS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHOSPHORYLATION; SPECIES DIFFERENCE;

AMINOPYRIDINES; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELL SIZE; DIABETIC NEPHROPATHIES; ENZYME ACTIVATION; ENZYME ACTIVATORS; FIBROSIS; HUMANS; INDOLES; ISOENZYMES; KIDNEY; KIDNEY FUNCTION TESTS; MACACA FASCICULARIS; MICE, INBRED C57BL; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEINURIA; RATS; SPECIES SPECIFICITY;

EID: 85018188825     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.237925     Document Type: Article

References (24)

1. Bilan VP, Salah EM, Bastacky S, Jones HB, Mayers RM, Zinker B, Poucher SM, and Tofovic SP (2011) Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 210:293-308.
2. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, and Bricogne G (2004) Refinement of severely incomplete structures with maximum likelihood in BUSTERTNT. Acta Crystallogr D Biol Crystallogr 60:2210-2221.
3. Boustany-Kari CM, Harrison PC, Chen H, Lincoln KA, Qian HS, Clifford H, Wang H, Zhang X, Gueneva-Boucheva K, Bosanac T, et al. (2016) A soluble guanylate cyclase activator inhibits the progression of diabetic nephropathy in the ZSF1 rat. J Pharmacol Exp Ther 356:712-719.
4. Calabrese MF, Rajamohan F, Harris MS, Caspers NL, Magyar R, Withka JM, Wang H, Borzilleri KA, Sahasrabudhe PV, Hoth LR, et al. (2014) Structural basis for AMPK activation: natural and synthetic ligands regulate kinase activity from opposite poles by different molecular mechanisms. Structure 22: 1161-1172.
5. Cameron KO, Kung DW, Kalgutkar AS, Kurumbail RG, Miller R, Salatto CT, Ward J, Withka JM, Bhattacharya SK, Boehm M, et al. (2016) Discovery and preclinical characterization of 6-chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic acid (PF-06409577), a direct activator of adenosine monophosphate-activated protein kinase (AMPK), for the potential treatment of diabetic nephropathy. J Med Chem 59: 8068-8081.
6. Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, Andreyev A, Quach T, Ly S, Shekhtman G, et al. (2013) AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 123:4888-4899.
7. Eid AA, Ford BM, Bhandary B, de Cassia Cavaglieri R, Block K, Barnes JL, Gorin Y, Choudhury GG, and Abboud HE (2013) Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 62:2935-2947.
8. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
9. Gallagher H and Suckling RJ (2016) Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes Obes Metab 18:641-647.
10. Gödel M, Hartleben B, Herbach N, Liu S, Zschiedrich S, Lu S, Debreczeni-Mór A, Lindenmeyer MT, Rastaldi MP, Hartleben G, et al. (2011) Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 121:2197-2209.
11. Hallows KR, Mount PF, Pastor-Soler NM, and Power DA (2010) Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Renal Physiol 298:F1067-F1077.
12. Inoki K and Huber TB (2012) Mammalian target of rapamycin signaling in the podocyte. Curr Opin Nephrol Hypertens 21:251-257.
13. Inoki K, Mori H, Wang J, Suzuki T, Hong S, Yoshida S, Blattner SM, Ikenoue T, Rüegg MA, Hall MN, et al. (2011) mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 121:2181-2196.
14. Kim D, Lee JE, Jung YJ, Lee AS, Lee S, Park SK, Kim SH, Park BH, Kim W, and Kang KP (2013) Metformin decreases high-fat diet-induced renal injury by regulating the expression of adipokines and the renal AMP-activated protein kinase/acetyl-CoA carboxylase pathway in mice. Int J Mol Med 32:1293-1302.
15. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith AV, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42:376-384.
16. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, et al. (2007) A role for AMPactivated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol 292:F617-F627.
17. Mihaylova MM and Shaw RJ (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13:1016-1023.
18. Otwinowski Z and Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
19. Rajamohan F, Reyes AR, Ruangsiriluk W, Hoth LR, Han S, Caspers N, Tu M, Ward J, and Kurumbail RG (2015) Expression and functional characterization of human lysosomal acid lipase gene (LIPA) mutation responsible for cholesteryl ester storage disease (CESD) phenotype. Protein Expr Purif 110:22-29.
20. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, et al. (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118:1645-1656.
21. Steinberg GR and Kemp BE (2009) AMPK in health and disease. Physiol Rev 89: 1025-1078.
22. Vallon V and Komers R (2011) Pathophysiology of the diabetic kidney. Compr Physiol 1:1175-1232.
23. Yuan F, Liu YH, Liu FY, Peng YM, and Tian JW (2014) Intraperitoneal administration of the globular adiponectin gene ameliorates diabetic nephropathy in Wistar rats. Mol Med Rep 9:2293-2300.
24. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, et al. (2011) Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol Renal Physiol 301:F1114-F1123.